Major improvements have been made in the treatment of myeloma. However, all patients, perhaps with some exceptions, eventually relapse, even after autologous stem cell transplantation (ASCT). In that setting, the combinations of new drugs, namely the IMiDs and the proteasome inhibitors along with steroids, give encouraging results in relapsed patients. The median progression-free survival (PFS) is 20 months with lenalidomide plus dexamethasone plus ixazomib and 26 months with lenalidomide plus dexamethasone plus carfilzomib. Monoclonal antibodies have emerged as an additional new treatment option. The antibody anti-SLAMF7, elotuzumab, in combination with lenalidomide plus dexamethasone gives a median PFS of 20 months. The antibody daratumumab, targeting CD38, alone has an outstanding activity in previously heavily treated patients. Its use in combination is ongoing. Transplantation remains a major treatment option. For patients who relapse at least 18 months from the initial ASCT, a second ASCT can be performed with an expected time to progression of 19 months from the time of transplantation. For patients relapsing earlier and/or with high-risk characteristics and who are still chemosensitive, with a suitable donor, an allogeneic transplantation can be considered. The optimal treatment combination and sequence remain to be determined.
Introduction
Autologous stem cell transplantation (ASCT) is the standard treatment for younger newly diagnosed patients with multiple myeloma (MM). However, ultimately all patients will experience relapse following ASCT. The number of treatment options after relapse to an autograft is increasing. 
Immunomodulatory drugs
Immunomodulatory drugs (IMiDs) were the first new drugs to join standard chemotherapy to improve the treatment of myeloma. They have a dual mechanism of action, involving both a direct tumoricidal activity and a immunomodulation. The tumoricidal effect occurs through several mechanisms, including disruption of stromal support, induction of tumor suppressor genes and activation of caspases. The immunomodulatory effects includes T-cell and natural killer (NK)-cell activation, and increased expression of death effector molecules, which lead to enhanced immune cell function. There are currently three major IMiDs, namely thalidomide, lenalidomide (Revlimid The overall response rate (ORR) was 32% with a two-year PFS of 20% and overall survival (OS) of 48%. At that time, the thalidomide dose range was high from 200 mg to 800 mg per day with a high toxicity, especially peripheral neuropathy. Currently, thalidomide is rarely given above 200 mg per day which is usually well tolerated. If combined to steroid, namely dexamethasone, the ORR increases to 46%. [ 
Proteasome inhibitors
Proteasome inhibitors block the degradation of intracellular proteins in the ubiquitin-proteasome system and trigger proteotoxic stress preferentially in multiple myeloma cells. [ 2 ; intravenous bolus or subcutaneous injection). Median progression-free survival was superior in the carfilzomib group compared to the bortezomib group (18.7 months vs. 9.4 months). Serious adverse events were reported in 48% of the patients in the carfilzomib group and in 36% of the patients in the bortezomib group. Importantly, the toxicity profiles differed between the two proteasome inhibitor groups, with cardiopulmonary events occurring more frequently in the patients treated with carfilzomib, but with higher neuropathy rates in the bortezomib group. Discontinuation rates were comparable in the two groups.
Recent phase-I and phase-II trials of the orally bioavailable proteasome inhibitor ixazomib showed that the drug has promising single-agent activity in relapsed myeloma along with a favorable toxicity profile and that addition of dexamethasone enhances the response rates. [ 
Triplet combinations incorporating an IMiDs and a proteasome inhibitor
IMiDs are now combined with other very active drugs and especially with the proteasome inhibitors and the monoclonal antibodies ( Table 1 ). The most active three drug combinations are currently bortezomib plus thalidomide and dexamethasone (VTD), lenalidomide (Revlimid ® ) plus dexamethasone with either bortezomib (RVD or VRD), carfilzomib (CRD) or ixazomib or with the monoclonal antibodies elotuzumab or daratumumab. HDAC inhibitors in different combinations are also under investigation. Btz: bortezomib; Carfil: suppress the z; CR/nCR: complete response/near complete response; Dex: dexamethasone; Elo: elotuzumab; Len: lenalidomide; mo: median months; NA: not available; ORR: overall response rate; OS: overall survival; Pano: panobinostat; PFS: progression-free survival; PR: partial remission; TD: thalidomide dexamethasone; TTP: time to progression; VGPR: very good partial remission; VTD: velcade thalidomide dexamethasone.
The superiority of a triplet combination over a doublet in the relapse setting post ASCT was first demonstrated in 2012. In a phase-III study that was limited to patients with a first relapse or progression after at least one prior ASCT, [ ) with that of thalidomide-dexamethasone (TD). VTD resulted in a significantly longer median time to progression (19.5 vs. 13.8 months), a higher complete response plus near-complete response rate (45% vs. 21%), and a longer median duration of response (17.9 vs. 13.4 months) compared to TD. However, peripheral neuropathy, infection, and thrombocytopenia were significantly more frequent with VTD.
In a phase-II study of bortezomib and dexamethasone in combination with lenalidomide in patients with RR MM, of whom 36% had received a prior ASCT, median progression-free and overall survival were 9. 31 .8% and 9.3% of patients in the respective groups. Adverse events of grade 3 or higher were reported in 83.7% and 80.7% of patients in the carfilzomib and control groups, respectively; 15.3% and 17.7% of patients discontinued treatment owing to adverse events. Importantly, patients treated with the three-drug regimen reported superior health-related quality of life and there was a trend toward improved overall survival in the carfilzomib group.
The phase-III TOURMALINE-MM1 study (NCT01564537) results reported at the 2015 Annual Meeting of the American Society of Hematology showed that addition of the oral proteasome inhibitor ixazomib to lenalidomide-dexamethasone improved median progression-free survival from 14.7 to 20.6 months and VGPR + CR rates from 39% to 48.1%, at comparable adverse event rates in RR MM patients that were not refractory to lenalidomide or proteasome inhibitor-based therapy. While other drug combinations including proteasome inhibitors (such as those including cyclophosphamide or adriamycin, both with dexamethasone) have been reported or are still being investigated, and with the limitations of cross-trial comparisons, the triple combination of carfilzomib-lenalidomide-dexamethasone as investigated in the ASPIRE trial should probably be considered as the current most effective proteasome inhibitor-based regimens in RR MM.
For pomalidomide, the most promising combinations are those with cyclophosphamide or bortezomib. In a phase-II trial involving patients with RR MM who were lenalidomide refractory and received at least two prior therapies, patients received pomalidomide 4 mg days 1-21 plus weekly dexamethasone 40 mg in a 28-day cycle, with or without oral cyclophosphamide 400 mg days 1, 8, and 15. The triple combination pomalidomide-cyclophosphamide-dex was superior with a rate of PR or better of 65%, a PFS of 9. Table 2 ). Elotuzumab has no single-agent activity in advanced MM; however, significantly improved progression-free survival was shown when elotuzumab was combined with lenalidomide-dexamethasone or bortezomib-dexamethasone (Table 1) . Various mechanisms explain the workings of these antibodies, which include direct induction of apoptosis, complement dependent cytotoxicity (CDC), antibody dependent cellular cytotoxicity (ADCC) or antibody-dependent cellular phagocytosis (ADCP). [39-41 van Of note, CD38 is also expressed in lungs leading to common infusion reactions, and red blood cells leading to inability to cross match blood in patients in need of transfusions.
Daratumumab
Daratumumab is a human IgG1 (κ subclass) antibody blocking the CD38 molecule. It binds specifically to amino acids 233-246 and 267-280 of CD38 that enables an optimal interaction between the Fc portion of the antibody and complement or antibody dependent cytotoxic cells. study had a dose escalation design and in part 2 different dosing schedules were devised. In part 1, the maximum tolerated dose was not reached. In 16 mg/kg cohort of part 2, the overall response rate (ORR) was 36% with 15 patients showing at least PR, including two patients with VGPR and two with CR. ORR were lower in the 8 mg/kg cohort (10%). Median PFS in the 16 mg/kg groups was 5.6 months, while 65% of responding patients had not progressed until 12 months of follow-up. Daratumumab infusion appeared to be safe. In part 2 of the GEN501 study, 48% of patients experienced infusion-related reactions which were mild (all grades, 71%; grade 3, 1%), mainly restricted to the first infusion.
The encouraging results of the GEN501 were corroborated by Lonial et al. in the SIRIUS (MMY 2002) trial which enrolled 106 patients -the majority refractory to bortezomib or lenalidomide and had received a median of 5 prior lines of treatment, including 80% with a prior ASCT. Patients treated with 16 mg/kg daratumumab, featured a PR in 29% with sCR in 3% of the patients. Median PFS was 3.7 months with a one year OS of 65%. 21% of those patients that were refractory to bortezomib, carfilzomib, pomalidomide, or lenalidomide showed PRs or better. [ The ORR was 31%, duration of response was 7.6 months and 46% of responders remained progression free at 1 year after a median follow-up of 9.3 month. In this combined analysis after a median follow-up of 14.8 months, estimated OS was 19.9 months. Importantly, ORR was similar irrespective of ISS, number of prior therapies and refractory status.
Isatuximab and MOR 202
Isatuximab has been evaluated in relapsed/refractory MM patients in a dose escalation study. With dosing up to 20 mg/kg the MTD was not reached and in 18 heavily pretreated patients a dose of 10 mg isatuximab induced at least PR in 33% including CR in 11%. [ In the randomized phase-III trial (ELOQUENT-2) in RR MM (1-3 prior therapies), elotuzumab (10 mg/kg) combined with lenalidomide-dexamethasone improved median PFS by 4.5 months (14.9 to 19.4 months), as compared to lenalidomide-dexamethasone. This PFS benefit was independent of age (patients 65 years of age or older), presence of del(17p), or creatinine clearance of less than 60 ml/min. Also the overall response rate was higher in the elotuzumab group compared to the control group (79% vs. 66%). [ Immune monitoring of patients included in GEN501 and SIRIUS trials showed robust immune effects (T cell increases, increased CD8+/CD4 + ratios, increased antiviral responses, and increased T cell clonality) which were surprising to observe in heavily pretreated, relapsed and refractory patients. Improved clinical responses were associated with changes in these parameters. Additionally, a subpopulation of regulatory T cells expressing high CD38 levels and known to be extremely immune suppressive were completely eliminated by daratumumab treatment. These data suggest a previously unknown immune modulatory role of daratumumab that may contribute to its efficacy, and a potential role for CD38 immune-targeted therapies. There has been however no data to direct clinicians in the timing of sASCT, that is, whether at biochemical or symptomatic relapse. In the EBMT database, since 1995, 38,741 MM patients were reported to be in first relapse post-ASCT; however, most patients (83%) did not undergo a sASCT. When examined in a temporal setting, though sASCT was performed in 4443 patients, there has been a constant increase in the sASCT year on year to more than 500 patients per year since 2012 (Figure 1 ). Figure 1 . Since 1995, evolution of autologous and allogeneic stem cell transplantation performed to treat relapse occurring after an initial autologous transplantation in Europe (EBMT registry). Table 3 . Autologous and allogeneic stem cell transplantation studies in the relapse setting postautograft.
Auto: autologous stem cell transplantation; Allo: allogeneic stem cell transplantation; CR/nCR: complete response/near complete response; mo: median months; NA: not available; NRM: nonrelapse mortality; OS: overall survival; PFS: progression-free survival; Pro: prospective; PR: partial remission; Retro: retrospective; RR: relapse rate; VGPR: very good partial remission.
The first prospective randomized trial studying sASCT versus nontransplant consolidation (NTC) after first relapse and reinduction with a bortezomib-containing regimen has been reported by Cook et This study, incorporated into the international relapsed myeloma guidelines, highlights several issues that need to be addressed prospectively. Though offering a dataset on which to base clinical decision making, the role of sASCT in the setting of IMiD or combined IMiD and PI usage remains to be clarified. Furthermore, the role of post-sASCT consolidation and maintenance has not been addressed. Both these issues will be addressed in the up and coming UKMRA Myeloma XII study (http://medhealth.leeds.ac.uk/info/410/haematological_oncology/1760/haematological_oncology) due to commence recruitment in Q2 of 2016. UKMRA Myeloma XII study aims, firstly, to determine what the impact on depth of response will be when sASCT conditioning is augmented by the addition of a proteasome inhibitor and, secondly, what will the influence on durability of response be with post-sASCT consolidation and maintenance therapy. In this study, induction treatment will use an Ixazomib-containing induction regimen (ixazomib/thalidomide/dexamethasone; ITD), which will build on the proven efficacy of PI/IMiD combinations. Furthermore, following the sASCT randomization comparing a conventional and an augmented transplant schema, an ixazomib-containing consolidation and maintenance strategy will be tested. Incorporated into this study is a comprehensive assessment to define the MRD negative rate postreinduction, post-sASCT and conversion after ITD consolidation.
The last issue that needs addressing is that of availability of sufficient PBSC for a sASCT. For many patients, it was not possible to collect enough hematopoietic stem cells or, for logistical reason enough stem cells were not collected and stored, that would support two transplants. Until recently there has been no data to indicate if re-mobilization after a prior ASCT is feasible. The myeloma X study has shown that PBSC can be remobilized successful in 55-60% of patients. There is an outstanding question, though, about whether such remobilized cells have any evidence of the replicative stresses induced by a previous transplant, either functionally or genomically. Myeloma X has not provided any evidence on this subject and no such data exists in the human system but, ongoing research will hopefully answer this issue in time.
Thus, with long-term follow-up analysis, a sASCT offers both a disease control durability and a survival advantage when compared to a NTC, after bortezomib-based reinduction therapy in patients with MM relapsing after a prior ASCT. These data are key for patient-centered clinical decision making. ] One-hundred sixty-nine consecutive patients underwent HLA typing at disease recurrence. The study was designed on the intent to treat principle and included only those patients who underwent HLA typing immediately after the relapse. Of the 169 consecutive patients evaluated, 75 had found a donor and 72 (96%) underwent an allograft after reduced-intensity conditionings. Twenty-four transplants were from a HLA-identical sibling (32%) and 48 from an unrelated donor (68%). The two-year nonrelapse mortality was 22% in patients with a HLA-compatible donor (donor group) versus 1% for those without (no donor group). In the first report, the two-year progression-free survival and 2-year overall survival were 42% and 54%; and 18% and 53% in the donor group and the no-donor group, respectively.[67 Patriarca ] the 5-year progression-free survival was 21% in the donor group and 3% in the no-donor group (p < .001) whereas, importantly, 5-year overall survival was 40% in the donor group and 19% in the no-donor group (p = .007), the difference to the advantage of the donor group being significantly higher in this updated report. By multivariate analysis, availability of a donor, chemosensitive disease at the time of the allograft and longer duration of salvage treatment were significant predictors for favorable progression free survival. Moreover, high-risk karyotype at diagnosis was significantly associated with shorter overall survival. Of note, the time interval from the autograft to relapse had no significant impact on clinical outcomes after the allograft. This study further confirms that significant differences in clinical outcomes between 'donor groups' and 'no donor groups' may be seen only after a number of years of follow-up.
The current paradigm for the treatment of multiple myeloma include novel agents with potent antimyeloma activity, their potentially curative combination with the graft-vs-myeloma effect, however, has unfortunately never been explored in well-designed large prospective studies though their efficacy in relapsed patients after an allograft has been reported in many studies. All together, given that myeloma patients invariably relapse despite the recent improvement in overall survival, the case may be made that relapsed patients after an autograft may most benefit from the potentially curative effect of graft versus myeloma and its combination with potent antimyeloma agents especially if high-risk features are present at diagnosis. 
Conclusions
Even though major therapeutic improvements have emerged to treat myeloma, all patients eventually relapse, perhaps with some exceptions following allogeneic transplantation and some new drug combinations. The treatment algorithm in the relapse setting has become confusing in contrast to the first line treatment where the sequence of induction followed, if eligible, by autologous stem cell transplantation and consolidation is well accepted. We suggest in Figure 2 , a treatment pathway starting with different reinduction options according to initial treatment and followed by a transplant or no transplant approach. The role of immunotherapy with the monoclonal antibodies in this treatment algorithm is currently under investigation but it will definitely be an important part of the treatment in the near future. 
Many questions remain
At relapse, should we start treatment at biochemical or at clinical relapse? Should we incorporate in the clinical relapse the new criteria that are used in the first-line treatment namely a bone marrow plasmacytosis above 60% and/or more than one bone lesion on MRI and/or a ratio of involved over uninvolved free light chain above 100? Do we need to perform an ASCT? There are strong arguments supporting the use of a second ASCT if the relapse occurs at least 18 months after the first ASCT. There is also the scenario of patients treated initially with a tandem ASCT and who relapse sometimes many years later. Can we perform a third transplant and if so what is the outcome? The EBMT is currently conducting a retrospective registry based analysis to answer this question.
Allogeneic transplantation is very much criticized mostly because of its NRM and morbidity. Toxicity has decreased substantially with the use of less myeloablative regimens but at the cost of an increased relapse rate. However, it remains the only potentially curable treatment of myeloma. Much effort will be made in the coming years to improve immunomodulation post allogeneic transplantation incorporating the new drugs. The checkpoint inhibitors may be an opportunity to increase the very potent antimyeloma allogeneic effect. For the time being, one should consider allogeneic transplantation in first relapse in a 'chemosensitive' disease. It is now very clear that it should not be proposed, as it was done in the past, as a 'last ditch' effort to control the disease.
How to obtain a new remission at relapse? It very much depends on the efficacy and toxicity of the previous treatments. Retreatment with the initial combination can be done as long as there is at least a treatment-free interval of 6 months and the treatment was efficacious with an acceptable toxicity. More often, if the first line treatment was bortezomib based, the relapse treatment will be lenalidomide based and vice versa. If a combination of bortezomib plus lenalidomide was given and patients are refractory to these two drugs, we now have access to pomalidomide and carfilzomib. The challenge is now how to treat the quadruple refractory patients.
Should we use a doublet or a triplet? Triplet combinations have shown to be superior both in the first line and the relapse setting with an increased response rate and improved PFS but less convincing results for OS. Triplet gives the opportunity to target more malignant clones at once and leaves less chance for an aggressive clone to emerge. However, at subsequent relapse, one will have access to less treatment option with the initial triplet use compared to the doublet and in the end OS may be similar. Which triplet to use? We will soon have access to at least four triplet options, three lenalidomide-dexamethasone based, namely plus carfilzomib, plus elotuzumab, or plus ixazomib. Except for the combination of lenalidomide dexamethasone plus carfilzomib which has a median PFS of 26 months, the two other combinations have a shorter PFS of around 20 months. The combination of bortezomib plus dexamethasone and panobinostat has a PFS of 11 months. For all four combinations, the toxicity is different as well as their potential efficacy for subpopulations such as high-risk cytogenetic patients.
How long should the treatment be? If the goal is to proceed to transplantation, either autologous or allogeneic, at least a partial remission should be obtained. As in the first-line setting, four cycles are usually given but if the patient has a continuous decrease in its monoclonal peak with an acceptable toxicity, six cycles can be done: the better the response before transplant the better the outcome. Outside of the transplant setting, continuous treatment (maintenance) until the next relapse is more frequently undertaken but side effects may be limiting, while for some patients who experience a very good persistent response a treatment free period can be considered. One remaining question is the dose of steroids and the length of its use. Usually, the dose of steroids is progressively tapered and stopped after one or two years, but this is very much related to the physician's choice. There is little evidence to assist this decision.
New treatment options are emerging, mostly immune interventions such as bispecific monoclonal antibodies, immune checkpoint inhibitors and CAR T cells. New treatment combinations will emerge with a shift in the treatment paradigm with less, if any, chemotherapy and more targeted drugs and immunotherapy. The first goal is to prolong survival but the ultimate one is cure.
